NCT02073994View on ClinicalTrials.gov

Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation

PHASE1CompletedINTERVENTIONAL
Enrollment

174

Participants

Timeline

Start Date

March 1, 2014

Primary Completion Date

January 4, 2024

Study Completion Date

January 4, 2024

Conditions
CholangiocarcinomaChondrosarcomaGliomaOther Advanced Solid Tumors
Interventions
DRUG

AG-120

AG-120 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with AG-120 until disease progression or development of other unacceptable toxicity

Trial Locations (12)

10065

New York

21218

Baltimore

33136

Miami

37203

Nashville

75390

Dallas

77030

Houston

78229

San Antonio

80045

Aurora

85258

Scottsdale

90095

Los Angeles

94800

Villejuif

02215

Boston

All Listed Sponsors
lead

Institut de Recherches Internationales Servier

OTHER

NCT02073994 - Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation | Biotech Hunter | Biotech Hunter